LEQEMBI(LEQEMBI)是新流行的老年痴呆症药物, 名为《2025年最佳发明》, 快速自我注射治疗疾病的早期阶段。 LEQEMBI®, a new at-home Alzheimer’s drug, named a 2025 TIME Best Invention, treats early stages of the disease with a quick self-injection.

LEQEMBI IQLIKTM (Lecanemab-irmb)是早期阿尔茨海默氏病的亚皮体自动注射器,被命名为2025年医学和医疗领域最佳发明。 LEQEMBI® IQLIK™ (lecanemab-irmb), a subcutaneous autoinjector for early Alzheimer’s disease, has been named a 2025 TIME Best Invention in medical and healthcare. 艾莎和Biogen开发的这种药物是首个已获批准用于家庭使用的抗粉样蛋白疗法, 允许轻度认知障碍或轻度痴呆症患者在初步临床阶段后自行治疗. Developed by Eisai and Biogen, it’s the first anti-amyloid therapy approved for at-home use, allowing patients with mild cognitive impairment or mild dementia to self-administer treatment after an initial clinic phase. 美国于2025年8月批准并于10月6日发射,在大约15秒内提供剂量,减少对IV注剂的需求,缓解保健系统的压力。 Approved in the U.S. in August 2025 and launched October 6, it delivers a dose in about 15 seconds, reducing need for IV infusions and easing healthcare system strain. 该药物在50个国家得到批准,还有更多的审查有待进行。 The drug is approved in 50 countries, with more reviews pending. 它带有关于粉样蛋白相关成像异常 (ARIA) 的警告,这些异常可能是严重的或致命的,特别是在ApoE ε4载体中. It carries a warning for amyloid-related imaging abnormalities (ARIA), which can be serious or fatal, particularly in ApoE ε4 carriers. 基因测试是建议,但无需进行。 Testing for the gene is advised but not required.